Clinical Trial: Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients

U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT06807593) titled 'Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients' on Jan. 29.

Brief Summary: The goal of this clinical research study is to learn if ustekinumab can help to control immune-related diarrhea and/or colitis in cancer patients.

Study Start Date: June 30, 2025

Study Type: INTERVENTIONAL

Condition: Cancer

Intervention: DRUG: Ustekinumab

Given by infusion

Recruitment Status: NOT_YET_RECRUITING

Sponsor: M.D. Anderson Cancer Center

Published by HT Digital Content Services with permission from Health Daily Digest....